WO2011071239A3 - 올리고머 복합체의 형성을 통한 난/불용성 활성물질의 가용화 방법 - Google Patents

올리고머 복합체의 형성을 통한 난/불용성 활성물질의 가용화 방법 Download PDF

Info

Publication number
WO2011071239A3
WO2011071239A3 PCT/KR2010/007066 KR2010007066W WO2011071239A3 WO 2011071239 A3 WO2011071239 A3 WO 2011071239A3 KR 2010007066 W KR2010007066 W KR 2010007066W WO 2011071239 A3 WO2011071239 A3 WO 2011071239A3
Authority
WO
WIPO (PCT)
Prior art keywords
partially soluble
oligomer composite
formation
active substances
insoluble
Prior art date
Application number
PCT/KR2010/007066
Other languages
English (en)
French (fr)
Other versions
WO2011071239A2 (ko
Inventor
김철환
고승학
심재성
권은경
Original Assignee
(주)바이오제닉스
최용환
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)바이오제닉스, 최용환 filed Critical (주)바이오제닉스
Priority to US13/505,011 priority Critical patent/US9139703B2/en
Priority to JP2012536653A priority patent/JP5629327B2/ja
Priority to EP10836135.3A priority patent/EP2511345B1/en
Publication of WO2011071239A2 publication Critical patent/WO2011071239A2/ko
Publication of WO2011071239A3 publication Critical patent/WO2011071239A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L93/00—Compositions of natural resins; Compositions of derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C08J3/126—Polymer particles coated by polymer, e.g. core shell structures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/02—Cellulose; Modified cellulose
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/26—Cellulose ethers
    • C08L1/28—Alkyl ethers
    • C08L1/286—Alkyl ethers substituted with acid radicals, e.g. carboxymethyl cellulose [CMC]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L3/00—Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
    • C08L3/02—Starch; Degradation products thereof, e.g. dextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/04—Alginic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/06—Pectin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/12—Agar or agar-agar, i.e. mixture of agarose and agaropectin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L61/00—Compositions of condensation polymers of aldehydes or ketones; Compositions of derivatives of such polymers
    • C08L61/04—Condensation polymers of aldehydes or ketones with phenols only
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L99/00—Compositions of natural macromolecular compounds or of derivatives thereof not provided for in groups C08L89/00 - C08L97/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

본 발명은 2종류의 친수성 천연고분자로부터 유래한 올리고머를 이용하여 소수성 동공구조를 갖는 구조체를 형성시키고, 난/불용성 성분을 동공구조에 봉입시키므로써, 난/불용성 물질의 자가 응집(self-aggregation)을 억제시키면서 열역학적 안정성을 증가시켜 효과적으로 가용화하는 올리고머 복합체의 형성을 통한 난/불용성 활성물질의 가용화 방법에 관한 것이다. 본 발명의 주요구성은 두 종류의 친수성 천연고분자로부터 유래한 올리고머를 혼합하여 물에서 용해시켜 동공구조가 형성된 올리고머 복합체를 제조하는 1단계와; 상기 올리고머 복합체에 난/불용성 물질을 첨가하여 올리고머 복합체의 소수성 동공구조에 이를 봉입시키는 2단계를 포함하는 것을 특징으로 한다.
PCT/KR2010/007066 2009-12-09 2010-10-15 올리고머 복합체의 형성을 통한 난/불용성 활성물질의 가용화 방법 WO2011071239A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/505,011 US9139703B2 (en) 2009-12-09 2010-10-15 Method of solubilizing poorly soluble/insoluble active material through formation of oligomer composite
JP2012536653A JP5629327B2 (ja) 2009-12-09 2010-10-15 オリゴマー複合体の形成による難溶性／不溶性活性物質の可溶化方法
EP10836135.3A EP2511345B1 (en) 2009-12-09 2010-10-15 Solubilization method for partially soluble / insoluble active substances through formation of oligomer composite

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0121886 2009-12-09
KR1020090121886A KR101138258B1 (ko) 2009-12-09 2009-12-09 올리고머 복합체의 형성을 통한 난/불용성 활성물질의 가용화 방법

Publications (2)

Publication Number Publication Date
WO2011071239A2 WO2011071239A2 (ko) 2011-06-16
WO2011071239A3 true WO2011071239A3 (ko) 2011-11-03

Family

ID=44146002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/007066 WO2011071239A2 (ko) 2009-12-09 2010-10-15 올리고머 복합체의 형성을 통한 난/불용성 활성물질의 가용화 방법

Country Status (5)

Country Link
US (1) US9139703B2 (ko)
EP (1) EP2511345B1 (ko)
JP (1) JP5629327B2 (ko)
KR (1) KR101138258B1 (ko)
WO (1) WO2011071239A2 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101320100B1 (ko) * 2010-11-10 2013-10-18 (주)바이오제닉스 엘라직산계 화합물 함유 조성물, 이를 이용한 화장용 조성물, 및 이들의 제조방법
KR102310364B1 (ko) * 2014-11-28 2021-10-08 (주)아모레퍼시픽 용해성이 우수한 인삼 조성물
EP3120838A1 (en) * 2015-07-20 2017-01-25 Opterion Health AG Aqueous solution comprising a polyphenol
RU2751193C2 (ru) * 2017-01-11 2021-07-12 Ферринг Б.В. Быстро распадающаяся фармацевтическая композиция
CN110475538B (zh) * 2017-03-31 2022-08-12 株式会社爱茉莉太平洋 提高穗花杉双黄酮稳定性的透明或半透明化妆品组合物
CN108125967A (zh) * 2017-12-25 2018-06-08 陕西佰傲再生医学有限公司 一种用于缓解银屑病的敷料及制备方法
KR20200071028A (ko) 2018-12-10 2020-06-18 서울대학교산학협력단 유산균 균주를 이용하여 제조된 올리고당을 포함하는 난수용성 물질의 수용액 가용화 조성물
KR102613981B1 (ko) 2020-04-27 2023-12-14 서울대학교산학협력단 난수용성 물질의 수용액 가용화 조성물 및 이를 이용한 난수용성 물질의 수용액 가용화 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060065585A (ko) * 2003-06-20 2006-06-14 어드밴스드 인 비트로 셀 테크놀로지스, 에스.엘 히알루론산 나노입자들

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR200205848Y1 (ko) * 2000-04-21 2000-12-01 임성근 다용도 전자식 화이트보드
WO2003059321A1 (en) * 2001-12-21 2003-07-24 Soane David S Use of oligomers and polymers for drug solublization, stabilization, and delivery
US20040228884A1 (en) * 2003-05-15 2004-11-18 Gupta Shyam K. Ion-pair delivery system for cosmetic and pharmaceutical compositions
US20080102114A1 (en) * 2004-04-23 2008-05-01 Panduranga Rao Koritala Microparticles and Nanoparticles for the Transmucosal Delivery of Therapeutic and Diagnostic Agents
US20080254078A1 (en) * 2005-09-16 2008-10-16 Peter Kauper Chitosan-Based Particles
US20110142890A1 (en) * 2006-05-24 2011-06-16 Advanced In Vitro Cell Technologies, S.A. Nanoparticles of chitosan and hyaluronan for the administration of active molecules
US20080160096A1 (en) * 2006-07-27 2008-07-03 Janos Berbely Polymeric nanoparticles by ion-ion interactions
EP2172193A1 (en) * 2008-10-02 2010-04-07 Capsulution Nanoscience AG Improved nanoparticulate compositions of poorly soluble compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060065585A (ko) * 2003-06-20 2006-06-14 어드밴스드 인 비트로 셀 테크놀로지스, 에스.엘 히알루론산 나노입자들

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN, Y. ET AL.: "Chitosan-Dextran Sulfate Nanoparticles for Delivery of an Anti-angiogenesis Peptide", LETT. PEPT. SCI., vol. 10, 2003, pages 621 - 629, XP008156082 *
CUI, Z. ET AL.: "Chitosan-based Nanoparticles for Topical Generic Immunization", J. CONTR. REL., vol. 75, 2001, pages 409 - 419, XP008156097 *
FERREIRA, I. ET AL.: "Encapsulation of Antioxidants by Spray-Drying", CHEM. ENG. TRANS., vol. 11, 2007, pages 713 - 717, XP008156121 *
LIU, Z. ET AL.: "Polysaccharides-based Nanoparticles as Drug Delivery Systems", ADV. DRUG DELIV. REV., vol. 60, 17 September 2008 (2008-09-17), pages 1650 - 1662, XP008156092 *

Also Published As

Publication number Publication date
KR101138258B1 (ko) 2012-04-24
KR20110065055A (ko) 2011-06-15
JP2013509481A (ja) 2013-03-14
JP5629327B2 (ja) 2014-11-19
EP2511345A2 (en) 2012-10-17
EP2511345A4 (en) 2014-07-23
US9139703B2 (en) 2015-09-22
WO2011071239A2 (ko) 2011-06-16
EP2511345B1 (en) 2018-12-19
US20120219604A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
WO2011071239A3 (ko) 올리고머 복합체의 형성을 통한 난/불용성 활성물질의 가용화 방법
WO2011008540A3 (en) Refreshing cream foundation in gel form
WO2008119943A3 (en) Enteric pharmaceutical capsules
WO2008039737A3 (en) A method of administering a film product containing a drug
EP1847257A3 (en) Solid preparation comprising enteric solid dispersion
WO2013158814A8 (en) Immediate release, abuse deterrent pharmaceutical compositions
WO2010074540A2 (ko) 음이온성 약물 함유 약제학적 조성물 및 그 제조방법
WO2010009034A3 (en) Method for treating atrophic age related macular degeneration
WO2010065784A3 (en) Methods, devices, and compositions for dermal filling
WO2011059215A3 (ko) 은 나노입자의 고상 합성방법 및 이에 의해 합성된 은 나노입자
WO2011031621A8 (en) High strength seamless alginate capsules
WO2011053037A3 (ko) 금나노입자의 제조방법
WO2011106423A3 (en) Acai and iridoid based formulations
WO2011087629A3 (en) Microcrystalline cellulose and calcium carbonate compositions useful as recompactible pharmaceutical excipients
WO2011106432A3 (en) Morinda citrifolia and iridoid based formulations
WO2011106417A3 (en) Garcinia mangostana l. and iridoid based formulations
WO2009006311A3 (en) Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
WO2010122583A3 (en) Oral pharmaceutical compositions of acid labile substances
BRPI0910037A2 (pt) método para fabricar polilactídeo estável
EP2524687A3 (en) Edible jelly-form composition, jelly-form preparation and method for producing jelly-form preparation
WO2009158250A3 (en) Apparatus and methods of forming package-on-package interconnects
WO2013079605A3 (en) Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
WO2013178788A3 (en) Manufacture of degarelix
MX350927B (es) Composicion inmunogenica.
WO2011056785A3 (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10836135

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 13505011

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012536653

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010836135

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE